1. Poupon RE, Balkau B, Eschwege E, et al. A multicenter trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324: 1548-1554.
2.
2. Colombo C, Setchell KD, Podda M, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr. 1990;117: 482-489.
3.
3. Ahrens EH Jr, Harris RC, MacMahon HE. Atresia of the intrahepatic bile ducts. Pediatrics. 1951;8: 628-647.
4.
4. Alagille D, Odievre M, Gautier M, et al. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental and sexual development, and cardiac murmur. J Pediatr. 1975;86: 63-71.
5.
5. Byrne JL, Harrod MJ, FriedmanJM, et al. del (20p) with manifestations of arteriohepatic dysplasia. AmJMed Genet. 1986;24: 673-678.
6.
6. Dahms BB, Petrelli M, Wyllie R, et al. Arteriohepatic dysplasia in infancy and childhood: a longitudinal study of six patients. Hepatology. 1992;2: 350-358.
7.
7. Keeffe EB, Pinson CW, Ragsdale J, et al. Hepatocellular carcinoma in arteriohepatic dysplasia. AmJ Gastroenterol. 1993;88: 1446-1469.
8.
8. Habib R, Dommergues JP, Gubler MC, et al. Glomerular mesangiolipidosis in Alagille syndrome (arteriohepatic dysplasia). Pediatr Nephrol. 1987;1: 455-464.
9.
9. Alagille D, Estrada A, Gautier M, et al. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr. 1987;110: 195-200.
10.
10. Riely CA, Cotlier E, Jensen PS, et al. Arteriohepatic dysplasia: a benign syndrome of intrahepatic cholestasis with multiple organ involvement. Ann Int Med. 1979;91: 520-527.
11.
11. Levy E, Bendayan M, Thibault L, et al. Lipoprotein abnormalities in two children with minimal biliary excretion. J Pediatr Gastroenterol Nutr. 1995;20: 432-439.
12.
12. Garcia RE, Moodie DS. Implications of childhood hypercholesterolemia. Cleve ClinJMed. 1990;57: 715-720.
13.
13. Sokol RJ. Medical management of neonatal cholestasis. In: Balistreri WF, Stocker JT, eds. Pediatric Hepatology. Philadelphia: Hemisphere Publishing; 1990:41-76.
14.
14. Motulsky AG. The genetic hyperlipidemias. N Engl J Med. 1976;294: 823-827.
15.
15. Poupon RE, Ouguerram K, Chretien Y, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology. 1993;17: 577-582.
16.
16. Ghent CA. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am J Gastroenterol. 1987;82: 117-118.
17.
17. Ramirez RO, Sokol RJ. Medical management of cholestasis. In: Suchy FJ, ed. Liver Disease in Children. St. Louis: Mosby; 1994:356-388.
19. Clerici C, Gentili G, Dozzini G, et al. Terapia cronica con acido ursodesossicolico in un bambino affecto da Sindrome di Alagille [Chronic therapy with ursodeoxycholic acid in a child with Alagille syndrome]. Pediatr Med Chir. 1993;15: 521-523.
20.
20. Nittono H, Tokita A, Hayashi M, et al. Ursodeoxycholic acid therapy in the treatment of biliary atresia. Biomed Pharmacother. 1989;43: 37-41.
21.
21. Balistreri WF, A-Kader HH, Heubi JE, et al. Effect of ursodeoxycholic acid (UDCA) on pruritus and serum cholesterol levels in patients with cholestasis associated with syndromic paucity of the intrahepatic bile ducts (Alagille syndrome) [abstract]. Hepatology. 1990;12(4 part 2):994-994.
